# Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)

> **NCT00892658** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 24 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00892658
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2019-11
- **Final completion:** 2020-12-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00892658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00892658, "Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00892658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*